PLETHICO

Plethico Pharmaceuticals Limited has informed the Exchange about the Intimation of Appointment of Director and Rename and Reconstitution of the Committee

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors at there meeting held on March 31, 2015, inter-alia, considered the following:- 1. Appointment of Mr. Deen Bandhu Roy, as an additional Director of the Company. 2. Appointment of Mrs. Meena Matani, as an additional Director of the Company. 3. Appointment of Ms. Anuradha Kumari, as an additional Director of the Company. 4.Acceptance of Resignation of Mr. Pramod K. Shrivastava, Director of the Company, effective from the conclusion of this meeting. 5. To file a application before the concerned authorities

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on February 14, 2015, inter-alia, considered the following :- 1. Acceptance of Resignation of Dr. G. N. Qazi, Independent Non-Executive Director of the Company, effective from the conclusion of this meeting. 2. Shifting of Corporate Office of the Company from Sabnam House, Plot No.A-15/16, Central Cross Road-B, M.I.D.C Andheri (E), Mumbai-400093 to Shop No: 262, Lower Ground Floor, Dreams the Mall, L B S Marg, Bhandup (W), Mumbai - 400078.

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on September 09, 2014, inter-alia, decided to postpone its Annual General Meeting which was scheduled on September 29, 2014 and make an application to the Registrar of Companies, Madhya Pradesh for extension of time for a period of three months for holding the AGM.

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of directors at their meeting held on August 13, 2014 inter-alia, considered the following:1) Fixing September 29, 2014 for holding the Annual General Meeting of the Members of the Company for the 15 months period ended March 31 ,2014 at the registered office of the company. 2) Acceptance of Resignation of Mr. Pranav Koshal, Independent Non- executive Director of the Company effective from the conclusion of this meeting.

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on January 24, 2014 has considered the following: (1) Extension of its current accounting/ financial year by a period of 3 (Three) months so as to align financial year of the Company in terms of provisions of Companies Act, 2013. As such, current accounting year shall be for a period of 15 (fifteen) months commencing from January 01, 2013 and ends on March 31, 2014. The subsequent accounting years, as such, shall commence from 1st April and end on 31st March every year.(2)

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 14, 2013, inter-alia, considered the following :(1) Fixing the June 28, 2013 for holding of the 20th Annual General Meeting of the members of the Company for the accounting year ended December 31, 2012. (2) Approval of text of advertisement for acceptance and renewal of deposits in accordance with the provisions of the Companies (Acceptance of Deposits) Rules, 1975, framed under section 58A of the Companies Act, 1956.

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on November 09, 2012, inter alia, consider the following :- (1) Acceptance of Resignation of Mr. Abhay Suhane, Independent Non-Executive Director of the Company, who has resigned from the Board of Directors of the Company on October 03, 2012; (2) Appointment of Mr. Hitesh Thakar as an Additional Director (Independent Non-Executive).

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors regret their inability to recommend any dividend for the year ended December 31, 2011, given the Global Financial Scenario and also the impending outcome of the FCCB issued by the Company.

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on June 03, 2011, has decided to defer the Annual General Meeting to a future date and for which the Company has filed an application to the Registrar of Companies, Madhya Pradesh & Chhattisargh, Gwalior for the extension of Annual General Meeting for a further period of 3 months under Section 166 of the Companies Act 1956.

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on April 13, 2011, has considered the options of managing the liabilities of the company through various initiatives such as amending the terms and conditions of the outstanding Foreign Currency Convertible Bonds Issued on October 2007("FCCBs), including but not limited to tenor, interest rate, yield to maturity, other methods of extinguishing FCCBs, including and not limited to repurchase, redemption, buyback, either wholly, partly or in tranches etc., or restructuring of

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company has, at its meetings held on February 14, 2011 considered the following: (1) Allotment of 20,00,000 warrants at a price of Rs.400/- per warrant, convertible into equity shares of Rs.10/- each fully paid up at a premium of Rs.390/- per share on a preferential allotment basis, to M/s Arum Investments Private Limited. (2) Approval of Statement of Advertisement under section 58A of the Companies Act, 1956 for acceptance of Deposits.

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company has, at its meeting held on December 08, 2010 decided the following: (1) To consider, approve, issue and allot 20,00,000 warrants (each warrant being convertible into one equity share of Rs. 10/-) at a price of Rs. 400/- per warrant, on preferential basis to a person / entities other than Promoter in accordance with provision of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 and its subsequent amendments made from time to time and other applicable rules, regulations and

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company has, at its meeting held on March 24, 2010 decided the following: (1) To raise up to US$ 100 Million equivalent to Indian rupees from the already Members approved limit US$ 40 Million equivalent to Indian rupees by way of Qualified Institutional Placement (QIP) and /Global Depository Receipts(GDRs) and/or American Depository Receipts (ADRs) and/or Foreign Currency Convertible Bonds (FCCBs) and/or any other security in the domestic / international market(s) subject to statutory approvals as may

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on March 28, 2008 has approved the following : 1) Audited financial results of the Company for the quarter and 15 months accounting period ended on December 31, 2007. 2) Re-appointment of Shri Shashikant Patel and Shri Chirag Patel as Chairman & Managing Director and Whole-time Director & Chief Executive Officer of the Company respectively for a further period of 3 years w.e.f. April 01, 2008 at a remuneration as may be decided by the Board of Directors within the limits pr